Arax Advisory Partners’s CareDx CDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.8K Buy
1,465
+980
+202% +$21.3K ﹤0.01% 3419
2026
Q1
$8.42K Buy
485
+125
+35% +$2.37K ﹤0.01% 2540
2025
Q4
$6.78K Sell
360
-513
-59% -$8.59K ﹤0.01% 2685
2025
Q3
$12.7K Buy
+873
New +$12.4K ﹤0.01% 2492
2025
Q1
– Sell
-265
Closed -$5.67K – 2727
2024
Q4
$5.67K Hold
265
– – ﹤0.01% 1696
2024
Q3
$8.28K Hold
265
– – ﹤0.01% 1499
2024
Q2
$4.12K Buy
+265
New +$3.2K ﹤0.01% 1678

Other funds holding CDNA

Arax Advisory Partners's CDNA Position: Q2 2026 in Review

Arax Advisory Partners increased its CareDx (CDNA) stake by 202% in Q2 2026, buying an estimated $21.3K and bringing the position to 1,465 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

Arax Advisory Partners first reported a position in CDNA in Q2 2024 and has held it in 7 quarters since. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

  • Arax Advisory Partners held 1,465 shares of CareDx worth $41.8K as of Q2 2026.
  • Arax Advisory Partners bought 980 CareDx shares in Q2 2026, an estimated $21.3K.
  • CareDx made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3419 holding.
  • Arax Advisory Partners first reported a position in CareDx in Q2 2024 and has held it in 7 quarters since.
  • 227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.